Behnemoon Mahsa, Borumandkia Zahra
Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Medical Center, Urmia University of Medical Sciences, Urmia, Iran.
J Cardiovasc Thorac Res. 2024;16(3):194-197. doi: 10.34172/jcvtr.33062. Epub 2024 Sep 20.
Mortality benefit of digoxin prescription in patients suffering from heart failure has been questioned many time. We evaluated these effects among admitted symptomatic heart failure patients.
We retrospectively divided our patients into two groups: group A (n=205) were digoxin prescribed, and group B (n=96) were digoxin naïve patients. Both groups' medical records were gathered for one year, and the study endpoints were compared between the two groups.
The mean age was 62.3±12.1 years and 54.8 % were male. All-cause mortality and readmission occurred in 26.7% and 31.7% of individuals, respectively, without significant differences between the two groups. However, in subgroup analysis, there was a significant relationship between in-hospital mortality and the presence of cardiovascular risk factors.
Digoxin might increase in-hospital mortality in patients with underlying cardiovascular risk factors.
地高辛处方对心力衰竭患者的死亡率益处已多次受到质疑。我们评估了住院有症状心力衰竭患者中的这些影响。
我们回顾性地将患者分为两组：A组（n = 205）为开具了地高辛的患者，B组（n = 96）为未使用地高辛的患者。收集两组患者一年的病历，并比较两组之间的研究终点。
平均年龄为62.3±12.1岁，男性占54.8%。全因死亡率和再入院率分别发生在26.7%和31.7%的个体中，两组之间无显著差异。然而，在亚组分析中，住院死亡率与心血管危险因素的存在之间存在显著关系。
地高辛可能会增加有潜在心血管危险因素患者的住院死亡率。
